Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR9114 intranasal spray study for influenza prevention in healthy adults
ISRCTN85449588Phase 2Recruiting
- Sponsor
- Leyden Labs
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised trial in influenza, Influenza A infection and influenza B comparing Intranasal CR9114 with Intranasal placebo (2 arms). Primary endpoints: Treatment-emergent adverse events and Viral load area under the curve by qRT-PCR. Started Aug 2026; status: recruiting.
02
Drugs
CR9114
03
Conditions
influenzaInfluenza A infectioninfluenza B
Beyond the preview
Go deeper on ISRCTN85449588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN85449588.